Clinical Trial Update: CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CD2 lozenges to prevent acute oral mucositis in head and neck cancer patients undergoing radiotherapy and chemotherapy has been withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• CD2 Lozenges

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Head and Neck Cancer, Oral Complications of Radiation Therapy | Phase 3 | Status: WITHDRAWN